Inogen, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

Summary of Significant Accounting Policies - Additional Information (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended						0 Months Ended		6 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended			12 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 Product Segment	Jun. 30, 2013	Mar. 07, 2014	Feb. 20, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 20, 2014 Inogen, Inc.	Feb. 20, 2014 Stockholders	Jun. 30, 2014 Service Contracts	Jun. 30, 2014 Medicare Service Reimbursement Programs	Jun. 30, 2013 Medicare Service Reimbursement Programs	Jun. 30, 2014 Medicare Service Reimbursement Programs	Jun. 30, 2013 Medicare Service Reimbursement Programs	Jun. 30, 2014 Medicare Service Reimbursement Programs rental revenue	Jun. 30, 2013 Medicare Service Reimbursement Programs rental revenue	Jun. 30, 2014 Medicare Service Reimbursement Programs rental revenue	Jun. 30, 2013 Medicare Service Reimbursement Programs rental revenue	Jun. 30, 2014 Accounts Receivable	Dec. 31, 2013 Accounts Receivable	Jun. 30, 2013 raw materials vendor one	Jun. 30, 2013 raw materials vendor two	Jun. 30, 2013 raw materials vendor three	Jun. 30, 2014 Total revenue	Jun. 30, 2013 Total revenue
Significant Accounting Policies [Line Items]
Fair Value Inputs, Long-term Revenue Growth Rate												23.40%	26.90%	25.00%	29.50%	71.70%	73.30%	72.10%	74.30%	21.10%	25.00%	17.30%	15.50%	11.10%	10.00%	10.00%
Accounts Receivable, Net, Current	$ 15,645		$ 15,645				$ 10,231													$ 3,300	$ 2,560
Extended service contracts			Lifetime of the patient								12 to 24 months
Accrual of product warranty liability	1,078		1,078				809	447
Number of deliverables qualifying as separate units			2
Deliverable standard warranty, period			3 years
Deliverable lifetime warranty, description			Lifetime of the patient								12 to 24 months
Estimation for sale of products			The Company estimates that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20%?per year, the Company estimates on average all patients will succumb to their disease within five years.
Rental revenue earned			30-day period
Unbilled Receivables	2,729		2,729				1,435
Cost Of Property Repairs And Maintenance	400	196	790	456
Property Plant And Equipment Salvage Value	$ 0		$ 0
Number Of Operating Segments			1
Reverse stock split ratio			3:1
Effective date of reverse stock split			Nov. 12, 2013
Common stock, par value	$ 0.001		$ 0.001			$ 16.00	$ 0.001
Common stock, shares issued	18,240,043		18,240,043			4,411,763	280,974
Number of shares sold									3,529,411	882,352
Common stock purchased by underwriters					99,550
Common stock, shares outstanding	18,240,043		18,240,043			14,259,647	280,974